US EditionNovo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
2 Articles
2 Articles
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
Key PointsNovo Nordisk has lost ground in the weight-loss drug market to Eli Lilly and telehealth companies.The company's new CEO is being far more aggressive, which bodes well.Novo's upcoming Wegovy pill is a prime opportunity to recapture market share.10 stocks we like better than Novo Nordisk › Over the past several years, GLP-1 agonist weight-loss drugs have evolved from a celebrity trend to arguably the hottest growth opportunity in the pha…
"They're leading now, and soon we'll be back," says Filip Knop, head of medical science at Novo Nordisk, regarding the competition with Eli Lilly. This year, the Danish pharmaceutical giant was overtaken by its American rival, and the new CEO announced drastic changes at the company's headquarters in Copenhagen. But can he put the company back at the forefront? Knop thinks so: "We have numerous promising medicines in development."
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
